Aldeyra Therapeutics, Inc. (ALDX)

Market Cap	356.05M
Revenue (ttm)	n/a
Net Income (ttm)	-64.88M
Shares Out	58.46M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	256,665
Open	6.06
Previous Close	6.08
Day's Range	5.96 - 6.21
52-Week Range	2.36 - 7.99
Beta	1.27
Analysts	Buy
Price Target	20.27 (+230.1%)
Earnings Date	Nov 10, 2022

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in...

• Industry: Biotechnology
• IPO Date: May 2, 2014
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: ALDX

Analyst Forecast

According to 14 analysts, the average rating for ALDX stock is "Buy." The 12-month stock price forecast is 20.27, which is an increase of 230.13% from the latest price.

Price Target

$20.27

(230.13% upside)

Analyst Consensus: Buy